Literature DB >> 30301689

In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization.

Patric Liang1, Chun Li1, Thomas F X O'Donnell2, Ruby C Lo1, Peter A Soden1, Nicholas J Swerdlow1, Marc L Schermerhorn3.   

Abstract

OBJECTIVE: Studies using hospital discharge data likely underestimate postoperative morbidity and mortality after lower extremity revascularization because they fail to capture postdischarge events. However, the degree of underestimation and the timing of postdischarge complications are not well-characterized.
METHODS: We used the American College of Surgeons National Surgical Quality Improvement Program procedure-targeted vascular databases from 2011 to 2015 to tabulate 30-day adverse events (in hospital and after discharge) for lower extremity bypass (LEB) and percutaneous vascular interventions (PVIs) performed for claudication and chronic limb-threatening ischemia (CLTI).
RESULTS: A total of 14,125 patients underwent lower extremity revascularization, 8909 patients (63%) with LEB and 5216 (37%) with PVI. For CLTI, total 30-day mortality was similar between PVI and LEB (2.3% vs 2.1%; P = .61), but in-hospital deaths only accounted for 43% of PVI mortality and only 65% of LEB mortality (P ≤ .001). Major adverse cardiac events occurred in 2.9% of PVI patients and 4.6% of LEB patients (P < .001), with postdischarge events accounting for 37% of PVI events and 18% of LEB (P ≤ .001). Although the 30-day reoperation rates were 14% for PVI and 18% for LEB (P < .001), almost one-half occurred after discharge (PVI 46% vs LEB 44%; P = .55). Any postoperative major adverse events (MAEs) occurred in 22% of patients after PVI and 31% after LEB, with more than one-half occurring after discharge (PVI 56% vs LEB 53%; P = .17). For claudicants, total 30-day mortality was 0.4% for PVI and 0.7% for LEB (P = .32), with the vast majority of events occurring after discharge (PVI 90% vs LEB 50%; P = .049). The 30-day reoperation rates were 5.2% for PVI and 8.0% for LEB (P < .001), with more than one-half occurring after discharge (PVI 63% vs LEB 53%; P = .09). Any MAEs occurred in 7.0% of patients after PVI and 17% after bypass, with the majority occurring after discharge (PVI 65% vs LEB 63%; P = .66).
CONCLUSIONS: Most MAEs occur less frequently after PVI than LEB. However, a significant number of major of adverse events after lower extremity revascularization occur after leaving the hospital, especially after PVI, which may overestimate its benefits compared with LEB if only in-hospital data are evaluated. These data demonstrate the importance of reporting 30-day rather than in-hospital outcomes when evaluating postoperative adverse events.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angioplasty; Chronic limb threatening ischemia; Lower extremity bypass; Revascularization; Stenting

Mesh:

Year:  2018        PMID: 30301689      PMCID: PMC6348035          DOI: 10.1016/j.jvs.2018.06.207

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  18 in total

1.  Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.

Authors:  D J Adam; J D Beard; T Cleveland; J Bell; A W Bradbury; J F Forbes; F G R Fowkes; I Gillepsie; C V Ruckley; G Raab; H Storkey
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

2.  Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft.

Authors:  Teviah Sachs; Frank Pomposelli; Allen Hamdan; Mark Wyers; Marc Schermerhorn
Journal:  J Vasc Surg       Date:  2011-08-31       Impact factor: 4.268

3.  Preoperative smoking habits and postoperative pulmonary complications.

Authors:  L G Bluman; L Mosca; N Newman; D G Simon
Journal:  Chest       Date:  1998-04       Impact factor: 9.410

4.  Infrainguinal percutaneous transluminal angioplasty or bypass surgery in patients aged 80 years and older with critical leg ischaemia.

Authors:  E Arvela; M Venermo; M Söderström; M Korhonen; K Halmesmäki; A Albäck; M Lepäntalo; F Biancari
Journal:  Br J Surg       Date:  2011-01-27       Impact factor: 6.939

Review 5.  End-stage renal disease and limb salvage.

Authors:  Houssam K Younes; Mark G Davies; Eric K Peden
Journal:  Methodist Debakey Cardiovasc J       Date:  2013-04

6.  End-stage renal disease and critical limb ischemia: a deadly combination?

Authors:  F Biancari; E Arvela; M Korhonen; M Söderström; K Halmesmäki; A Albäck; M Lepäntalo; M Venermo
Journal:  Scand J Surg       Date:  2012       Impact factor: 2.360

7.  Nationwide Trends of Hospital Admission and Outcomes Among Critical Limb Ischemia Patients: From 2003-2011.

Authors:  Shikhar Agarwal; Karan Sud; Mehdi H Shishehbor
Journal:  J Am Coll Cardiol       Date:  2016-03-21       Impact factor: 24.094

8.  A decade experience with infrainguinal revascularization in a dialysis-dependent patient population.

Authors:  Pranay Ramdev; Sunil S Rayan; Malachi Sheahan; Allen D Hamdan; Frank W Logerfo; Cameron M Akbari; David R Campbell; Frank B Pomposelli
Journal:  J Vasc Surg       Date:  2002-11       Impact factor: 4.268

9.  An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety.

Authors:  Natalia N Egorova; Stephanie Guillerme; Annetine Gelijns; Nicholas Morrissey; Rajeev Dayal; James F McKinsey; Roman Nowygrod
Journal:  J Vasc Surg       Date:  2010-01-04       Impact factor: 4.268

10.  Long-term limb salvage and survival after endovascular and open revascularization for critical limb ischemia after adoption of endovascular-first approach by vascular surgeons.

Authors:  Hasan H Dosluoglu; Purandath Lall; Linda M Harris; Maciej L Dryjski
Journal:  J Vasc Surg       Date:  2012-05-05       Impact factor: 4.268

View more
  3 in total

1.  Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis.

Authors:  E Hope Weissler; Yongfei Wang; Jordan M Gales; Dmitriy N Feldman; Shipra Arya; Eric A Secemsky; Herbert D Aronow; Beau M Hawkins; J Antonio Gutierrez; Manesh R Patel; Jeptha P Curtis; W Schuyler Jones; Rajesh V Swaminathan
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

2.  Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.

Authors:  Eva Freisinger; Jeanette Koeppe; Joachim Gerss; Dennis Goerlich; Nasser M Malyar; Ursula Marschall; Andreas Faldum; Holger Reinecke
Journal:  Eur Heart J       Date:  2020-10-07       Impact factor: 29.983

3.  Discrete Event Simulation Model for Cost-Effectiveness Evaluation of Screening for Asymptomatic Patients with Lower Extremity Arterial Disease.

Authors:  Vojtěch Kamenský; Vladimír Rogalewicz; Ondřej Gajdoš; Gleb Donin
Journal:  Int J Environ Res Public Health       Date:  2022-09-19       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.